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Antibiotic prophylaxis has been utilized during the initial phases of myeloablative hematopoietic 
stem cell (HCT) transplantation for over two decades.  However, the optimal regimen in terms of 
both cost and clinical effectiveness is unclear.  We retrospectively compared the clinical and 
microbiological impact of a change in antibiotic prophylaxis practice from ceftazidime (n=216 
patients with HCT in 2000 – 2002) to levofloxacin (n=219 patients, August 2002 – 2005) in 
patients receiving myeloablative conditioning. Levofloxacin prophylaxis was associated with 
fever and a change in antibiotic during neutropenia, but this strategy was not associated with 
any adverse outcomes.  Patients receiving levofloxacin had lower rates of significant bacteremia 
than those receiving ceftazidime (day 100, 19.2% vs. 29.6%, p=0.02).  Use of levofloxacin was 
associated with lower antibiotic acquisition costs.  There was no deleterious impact from 
levofloxacin prophylaxis on survival, emergence of antibiotic resistance, detection of Clostridium 
difficile antigen in stool, incidence of viridans group streptococcal bacteremia or Pseudomonas 
infections.  There was a trend towards lower rates of bacteruria, wound and bacterial respiratory 
infections in the levofloxacin than in the ceftazidime group, but these differences were not 
statistically significant.  These data support the use of levofloxacin as prophylaxis in 





Bacterial infections are the single most common cause of infection related mortality, accounting 
for 36% of such deaths after allogeneic hematopoietic cell transplant (HCT) 1.  The risk of 
bacterial infection is largely mediated by neutropenia, defined as an absolute neutrophil count 
(ANC) < 500 cells/μL in blood 2,3,3. About 20% of neutropenic cancer patients will develop an 
episode of bacteremia, and delayed initiation of antibiotics until an infection is documented by 
culture may result in excess mortality in these patients 4.  Accordingly, antibiotic prophylaxis and 
empirical therapy are often employed as bacterial infection risk reduction strategies. Antibiotic 
prophylaxis starts at the onset of neutropenia and continues until engraftment 5. Although this 
approach may prevent some bacterial infections, leading to reduced mortality 6,7, the 
disadvantages of prophylaxis include increased antibiotic exposure with resulting higher drug 
costs, toxicity, and the potential for development of antibiotic resistance in bacteria. Empirical 
antibiotic therapy is initiated at the onset of fever in neutropenic patients. The advantage of this 
approach is decreased antibiotic exposure compared to the prophylaxis strategy, while the 
disadvantages include higher rates of infection, and the possibility that infections may advance 
to a critical stage before the onset of fever and the initiation of antibiotic treatment.  In HCT 
recipients a sequential strategy is most commonly employed using antibiotic prophylaxis with 
onset of neutropenia, followed by a change to a different (empiric) antibiotic with onset of fever.  
The Fred Hutchinson Cancer Research Center (FHCRC) has used antibiotic prophylaxis 
in allogeneic HCT recipients for the last 2 decades. In 2002, the FHCRC elected to transition 
from using ceftazidime to levofloxacin for antibacterial prophylaxis in this patient population. 
Ceftazidime is a third generation cephalosporin with activity against Pseudomonas aeruginosa 
and other Gram-negative rod (GNR) bacteria but with a poor Gram-positive spectrum. 
Levofloxacin is a fluoroquinolone with enhanced Gram-positive activity (including against 
Staphylococcus aureus) along with activity against Pseudomonas and other GNRs. The 
rationale underlying this transition was that levofloxacin has a broader spectrum of activity, 
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requires only once daily dosing of 750 mg intravenously or orally, and is significantly less 
expensive than 2 grams of ceftazidime administered intravenously every 8 hours. Oral 
levofloxacin has excellent bioavailability and is dramatically less expensive than intravenous 
ceftazidime for those patients who can tolerate oral medications. 
The initiation of this change was associated with a mandate to monitor the outcome of 
this policy.  In particular, we sought to determine if levofloxacin use was associated with an 
increased risk of GNR bacteremia due to quinolone resistant bacteria, a shift in the spectrum of 
bacterial pathogens causing disease, and an increased incidence of Clostridium difficile colitis 
since quinolone use is a risk factor for this infection 8. We carried out a retrospective analysis of 
two consecutive treatment cohorts to compare the following outcomes during the first 100 days 
following transplantation: fever, failure of prophylaxis (i.e., change of antibiotic), number and 
types of documented bacterial infections (including bacteremias), emergence of antibiotic 
resistance, use of antibiotic and antifungal medications, and costs of those medications.  Entry 
into and days spent in the intensive care unit (ICU) were assessed as surrogate markers for 
sepsis.  Relapse and mortality in the three years following transplantation were also described.   
 
Patients and methods 
Data collection 
The study population consisted of consecutively admitted adult recipients of myeloablative 
allogeneic HCT at the Seattle Cancer Care Alliance (SCCA) from July 2000 – December 2004, 
with inpatient visits at the University of Washington Medical Center and outpatient follow-up at 
the SCCA clinic. Patients received either ceftazidime or levofloxacin as prophylaxis during 
neutropenia. Pediatric patients were excluded. Ceftazidime was the standard antibacterial 
prophylaxis during the study period from 2000 to 2002.  After August of 2002, levofloxacin 
prophylaxis became standard practice.  Data were collected from pharmacy charts for 
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antibacterial and antifungal medications, and electronic medical records for fever, ANC, 
bacterial culture and antibiotic resistance information. 
Definitions 
Underlying disease was classified as advanced for all patients not in remission, patients with 
acute nonlymphoblastic leukemia in second or later remission, and patients with acute 
lymphoblastic leukemia in third remission or later.  Patients with chronic myeloid leukemia were 
classified as having advanced disease when in blast crisis at time of transplant.  All other 
patients were classified as not having advanced disease.  
Infections were documented following standard practices at the FHCRC/SCCA.  Fever 
was defined in this study as an oral temperature of 38.3°C or higher. Blood cultures were 
obtained in patients with temperatures >38.0°C, with two sets of culture bottles (aerobic, 
anaerobic, mycobacterial/fungal = 1 set) obtained with initial fever and then daily sets obtained 
with ongoing fever.  Blood cultures were also obtained with hemodynamic instability, chills, and 
at least weekly when receiving steroids > 0.5 mg/kg since this may mask a fever. Urine cultures 
were obtained with fever or urinary complaints.  Clostridium difficile ELISA for common antigen 
and Toxin A was sent for diarrhea or fever and abdominal pain. Bronchoscopy with 
bronchoalveolar lavage (BAL) was obtained in patients with pulmonary infiltrates or nodules 
seen on radiographic images.  
Bacteremic episodes were defined by any positive blood culture and summarized over 
two overlapping time periods: first, during the initial period of neutropenia, and second, anytime 
in the first 100 days after transplant.  The beginning of the neutropenic period was defined by 
the first day after conditioning that the ANC value fell below 500, and ended with the first day 
that value exceeded 500.  In patients with an initial neutropenic period that ended on transplant 
day +1 or before, infections during the second neutropenic period related to transplantation 
were described instead.  Within each time period, additional positive cultures for the same 
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organism recovered within 7 days of previous positive culture were considered part of the 
original episode, whereas positive cultures for different organisms on different days were 
considered separate episodes.  A polymicrobial episode was defined by positive cultures for two 
or more organisms on the same day. Analysis of bacteremic episodes was also performed 
excluding coagulase-negative staphylococci which were the most common isolates in our HCT 
recipients but have low pathogenic potential.   
Infections identified through other sources during the first 100 days post-transplant were 
also summarized.  Bacteruria was defined as at least 1+ growth of a pure culture; pyuria is not 
considered a reliable indicator of urinary tract infection in neutropenic patients and mixed 
bacteria on culture are associated with contamination during collection.  Wound infection was 
microbiologically documented through biopsy of subcutaneous tissue and excluded normal flora 
from non-sterile sites.  Respiratory tract infection was diagnosed via sputum, BAL fluid, tracheal 
aspirate and/or lung biopsy, with isolation of a credible pulmonary pathogen and excluding 
normal oral flora such as viridans streptococci, coagulase negative staphylococci, 
stomatococcus and diphtheroids. 
Failure of prophylaxis was defined as a change in antibiotic therapy, including a 
discontinuation of the initial treatment and use of additional drugs.  Since our description 
includes all further antibiotic treatment within the first 100 days post-transplant, “additional 
therapies” may include the original prophylaxis agent. 
The burden of antibiotic use was quantified by number of “antibiotic days” during days -5 
to +100 relative to transplant.  An “antibiotic day” was defined as treatment with a single 
antibiotic on one day; one day’s treatment with two antibiotic therapies was counted as two 
antibiotic days, and so on.  Thus, each patient’s total antibiotic days was calculated by summing 
up the number of days spent on each antibiotic therapy.  To estimate the monetary cost of each 
patient’s antibiotic treatment, we considered only the price paid by the clinic to acquire the 
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medicines and ignored the cost of infusion.  Based on common practice in our clinics, if 
treatment was given before day +21, we assumed that the IV cost was applicable.  If given past 
day +21, the oral usage cost was applied.  Patients with incomplete data on duration for 
selected antibiotics were excluded from analysis of antibiotic use and cost.   
Antifungal use and cost were summarized in a similar way to antibiotics.  Fluconazole is 
used routinely at the FHCRC/SCCA for antifungal prophylaxis in HCT. However, there is some 
variability in initial antifungal prophylaxis based on risk factors for mould infection. Thus, we 
restricted our attention to the subgroup of patients who received fluconazole as initial 
prophylactic therapy and described the switch to non-fluconazole (mould active) antifungal 
therapy after the initial transplant period. Patients with incomplete data on duration for selected 
antifungals were excluded from this analysis. 
Statistical analysis 
Patient characteristics were compared across cohorts via Chi-squared test for categorical data 
and t-test for continuous data.  Cumulative incidence curves were used to estimate the 
probabilities of the time-to-event outcomes: fever, change in antibiotic regimen, bacteremia, 
bacteruria, wound infection, respiratory tract infection and relapse-free survival. Relapse and 
death in the first 100 days were treated as competing risks for all infectious disease outcomes. 
The statistical significance of differences in event rates was evaluated with the proportional 
hazards regression model. The probability of entry into the ICU was estimated using a logistic 
regression model.  Within the subset of patients treated in the ICU, the number of days spent in 
the ICU was compared across cohorts via linear regression model. Factors considered as 
potential confounders of the relationships between the prophylactic antibiotic and the outcomes 
included age, sex, donor type (related vs. unrelated), receipt of total body irradiation (TBI), and 
cell source (peripheral blood stem cells or bone marrow).  Such factors were retained in the 
model if their presence influenced the coefficient of interest (use of levofloxacin vs. ceftazidime) 
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by 10% or more.  Reported p-values are two-sided, and based on the Wald statistic. No 
adjustments were made for multiple comparisons. 
 
Results 
The populations in the two different antibiotic prophylaxis groups were fairly similar with respect 
to age, diagnosis and donor type. Table 1 describes the patient characteristics by prophylaxis 
regimen.  Significantly more patients in the ceftazidime group received bone marrow rather than 
a peripheral blood stem cell (PBSC) transplant, as compared to the levofloxacin group (p=0.02).  
There was a significantly higher proportion of men than women among levofloxacin recipients 
compared to ceftazidime recipients (p=0.02).  The distribution of conditioning regimens varied 
by prophylaxis regimen, but this difference did not reach statistical significance. 
Patients who received levofloxacin as their first prophylaxis regimen were significantly 
more likely to have a fever early after initiation of the prophylactic antibiotic, as compared to 
patients who initially received ceftazidime (estimates at day 30 were 69.0% (95% confidence 
interval (CI) 62.8 – 75.2%) and 53.7% (95% CI 47.1 – 60.4%), respectively, p=0.004 after 
adjustment for cell source and donor type, Figure 1).  Fevers occurred at a median of 5 days 
(range 0 – 57 days) after initiation of the original prophylaxis regimen.  Similarly, more patients 
receiving levofloxacin prophylaxis experienced a failure of their initial prophylaxis (p<0.001).  
Changes in antibiotic regimen occurred at a median of 7 days (range 1 – 24 days) after the start 
of the original regimen.  Table 2 describes the therapies that patients received after failing initial 
prophylaxis. 
The prophylaxis groups did not differ with regard to overall antibiotic use: the median 
number of antibiotic treatment days per patient was 34, range 6 – 120 days in the ceftazidime 
group vs. median 31, range 3 – 168 days in the levofloxacin group, based on complete data 
from 171 ceftazidime treated patients and 197 levofloxacin treated patients.  The average 
antibiotic acquisition costs incorporating all antibiotics used in the study period were significantly 
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lower for levofloxacin than ceftazidime recipients: median $618, range $33 – 3378 vs. median 
$922, range $216 – 3158, respectively (p=0.001).  Among the 172 ceftazidime recipients and 
193 levofloxacin recipients who received fluconazole antifungal prophylaxis, there was no 
difference between groups in overall use of antifungals including use of mould active agents.  
Antifungal acquisition costs also did not vary by antibiotic prophylaxis cohort. 
The probability of at least one case of bacteremia in the first 100 days after transplant 
did not vary by group (p=0.15).  However, when single-organism coagulase-negative 
Staphylococcus (CoNS) infections were excluded, the levofloxacin group had a significantly 
lower probability of bacteremia than the ceftazidime group (p=0.02).  The estimated probabilities 
at day 100 were 29.6% (95% CI 23.5 – 35.7%) for the ceftazidime group and 19.2% (95% CI 
14.0 – 24.4%) for the levofloxacin group (Figure 2).   
The spectrum of bacteria causing bacteremia was similar across groups, although the 
number of infections for each Gram-positive bacterium was lower in the levofloxacin cohort than 
the ceftazidime cohort (Table 3).  The five episodes of Acinetobacter bacteremia in the 
levofloxacin group occurred in three subjects; two patients with one episode each and one 
patient with three episodes. One patient had infection with antibiotic resistant Acinetobacter in 
the levofloxacin cohort (Table 4). 
The incidence of bacteremia in the initial post-transplant period of neutropenia did not 
vary by group, even when the single-organism CoNS infections were excluded.  Overall, the 
period of neutropenia started on average at day +2, with a range from day 0 to 9; the median 
end time was day +17, with a range from day 2 to 37.  The average duration of the initial post-
transplant neutropenic period was 14 days, with a range of 1 to 34 days.  There were no 
dramatic differences between groups in the spectrum of bacteria causing bacteremia during 
neutropenia. 
For sources of infection other than blood, there were no significant differences between 
prophylaxis groups in rates of infections in the first 100 days after transplant.  There was a trend 
 10
suggesting the incidence of wound infection was lower in the levofloxacin than the ceftazidime 
cohort, but this difference did not reach statistical significance (day 100 estimates 4.1% (95% CI 
1.5 – 6.7%) and 8.8% (95% CI 5.0 – 12.6%) respectively, p=0.10).  There was no difference in 
the probability of at least one respiratory bacterial infection episode between the cohorts (day 
100 estimates 11.6% (95% CI 7.3 – 15.8%) for ceftazidime and 10.0% (95% CI 6.1 – 14.0%) for 
levofloxacin groups). The incidence of least one positive urine culture in the first 100 days after 
transplant did not differ significantly between ceftazidime and levofloxacin recipients: 22.7% 
(95% CI 17.1 – 28.3%) and 16.9% (95% CI 11.9 – 21.9%), respectively.  However, male and 
female patients had significantly different experiences of this outcome: 11 of 132 (8%) men in 
the levofloxacin group and 2 of 107 (2%) men in the ceftazidime group had at least one positive 
urine culture, while 26 of 87 (30%) women in the levofloxacin group and 47 of 109 (43%) 
women in the ceftazidime group had at least one positive urine culture.   
The probability of at least one positive blood (excluding CoNS), urine, wound, or 
respiratory culture in the first 100 days was estimated in order to assess the overall burden of 
infections. These estimates were not significantly different between prophylaxis groups (Figure 
3).  However, among patients with at least one infection of any type, patients in the ceftazidime 
group were significantly more likely than patients in the levofloxacin group to have had an 
infection in 2 or more sites (36% (38/107) vs. 20% (17/87), respectively, p=0.02).      
There was no significant difference in rates of detection of Clostridium difficile either by 
Toxin A or common antigen in the stool between the two prophylaxis cohorts during the first 100 
days after transplant. Of those subjects undergoing testing to diagnose possible Clostridium 
difficile disease, Clostridium difficile Toxin A was detected in 8.8% (95% CI 5.0 – 12.6%) of 
subjects in the ceftazidime group and 6.4% (95% CI 3.2 – 9.6%) of subjects in the levofloxacin 
group; Clostridium difficile antigen was detected in 27.8% (95% CI 21.8 – 33.8%) of subjects in 
the ceftazidime group and 20.1% (95% CI 14.8 – 25.4%) of subjects in the levofloxacin group. 
Ceftazidime recipients were more likely than levofloxacin recipients to have entered the ICU 
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during the first 100 days after transplant: 22% vs. 13%, p=0.03.  However, the incidence of ICU 
treatment within the first 100 days after transplant decreased over time in the study cohort: 19% 
among those transplanted in 2000, 25% in 2001, 16% in 2002, 18% in 2003, and 6% in 2004 
(p=0.004).  Thus, the difference between prophylaxis groups may be due to advances in care in 
the later time period of levofloxacin use.  Among those treated in the ICU, the number of days 
spent there did not differ between groups: median 4, range 1 – 60 days in the ceftazidime group 
vs. median 13, range 1 – 54 days in the levofloxacin group, p=0.42.  Also, the proportion of 
patients who died within 100 days of transplant after treatment in the ICU did not differ between 
groups: 38% in the ceftazidime group vs. 46% in the levofloxacin group.   
The use of levofloxacin instead of ceftazidime for prophylaxis did not adversely affect 
relapse-free survival (RFS).  At three years post-transplant, RFS was 57.1% (95% CI 50.5 – 
63.7%) in the levofloxacin group and 50.4% (95% CI 43.8 – 57.1%) in the ceftazidime group 
(Figure 4).  After adjusting for cell source and TBI exposure, the hazard ratio of RFS for the 
levofloxacin group relative to the ceftazidime group was 0.81 with 95% CI 0.62 – 1.07 and 
p=0.13. 
There were 26 deaths within 100 days of transplant in the ceftazidime group, with 14 
autopsies performed and 8 documented bacterial infections contributing to death (3 
Enterococcus species, 2 Staphylococcus aureus, 2 polymicrobial and 1 Myocobacterium avium 
complex). There were 26 deaths within 100 days of transplant in the levofloxacin group, with 6 
autopsies performed and 7 bacterial infections documented as contributing to death (3 
Enterococcus species including one vancomycin resistant enterococcus, 1 Acinetobacter, 1 





Several randomized, placebo controlled trials have documented the beneficial effects of 
levofloxacin prophylaxis in reducing rates of fever and infection in cancer patients with 
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neutropenia 9,10  and reducing mortality in neutropenic patients 11,12. Levofloxacin has several 
attractive characteristics including a broad spectrum of activity against Gram-negative and 
Gram-positive pathogens, once daily dosing, high oral bioavailability, excellent safety profile, 
and low cost. Some investigators have advocated caution in the adoption of levofloxacin for 
prophylaxis based on concerns about the potential for emergence of antibiotic resistance and a 
possible increase in enteric infections such as caused by Clostridium difficile 13.  Indeed, several 
studies have shown that fluoroquinolone use is a major risk factor for C. difficile colitis 14,15,15.  
Bucaneve reported that 10 of 13 Gram-negative rods isolated from the blood of patients 
receiving levofloxacin prophylaxis were resistant to levofloxacin 9. Furthermore, levofloxacin 
prophylaxis at 500 mg daily has been associated with an increased incidence of viridans group 
streptococcal bacteremia in autologous transplant recipients 16. Recognizing the potential 
deleterious consequences from instituting levofloxacin prophylaxis, we sought to monitor the 
clinical and microbiological impact of a change from ceftazidime to levofloxacin for antibacterial 
prophylaxis in allogeneic HCT recipients receiving myeloablative conditioning.  
 Patients receiving 750 mg levofloxacin per day as prophylaxis had a significantly higher 
probability of developing a fever (69.0%) compared to patients receiving 2 gm ceftazidime three  
times daily (53.7%), though the median time to fever was the same in febrile patients (5 days). 
This higher incidence of fever in the levofloxacin cohort led to a higher probability of changing 
antibiotics (63.5%) compared to the ceftazidime cohort (45.4%), reflecting the practice of 
starting a different empirical antibiotic in neutropenic patients who develop a fever on 
prophylaxis.  Patients with febrile neutropenia were most commonly switched to ceftazidime in 
the levofloxacin prophylaxis group, while patients in the ceftazidime prophylaxis group were 
most commonly switched to imipenem (Table 2). Vancomycin was used at similar rates in both 
groups. Despite the higher incidence of fever in the levofloxacin group, the use of mould active 
antifungal medications was similar between groups.  Thus the lower cost of Levofloxacin 
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prophylaxis as well as the lower cost of Ceftazidime as initial secondary therapy over Imipenem 
contributed to the markedly lower total antibiotic cost that we documented in this analysis.  
Ceftazidime prophylaxis resulted in a reduced rate of febrile episodes post-HCT as 
compared to levofloxacin prophylaxis.   Interestingly, documented bacteremia (excluding CoNS 
which is not susceptible to levofloxacin or ceftazidime) was less frequent among patients 
receiving levofloxacin prophylaxis.  In addition, rates of bacteruria, wound infection, isolation of 
a bacterial pathogen from respiratory culture, and Clostridium difficile antigen or toxin detection 
in stool were consistently lower in the levofloxacin group, although not statistically significantly 
different. Clostridium difficile toxin detection in stool provides evidence of toxigenic bacteria, 
whereas the antigen may be detected with either toxigenic or non-toxigenic strains of 
Clostridium difficile.   Antibiotic susceptibility profiles were monitored for each bacterial isolate 
and there was no trend towards isolation of more resistant bacteria in the levofloxacin cohort.  
Three patients in the levofloxacin prophylaxis group had Acinetobacter bacteremia, an infection 
that was not found in the ceftazidime cohort, but these bacteria were sensitive to both 
levofloxacin and ceftazidime for 2 of the 3 patients (Table 4).  Increased rates of Pseudomonas 
infection or viridans group streptococcal bacteremia did not become apparent with levofloxacin 
prophylaxis, despite some concerns in the literature regarding these pathogens emerging with 
levofloxacin use (Pseudomonas) or quinolones in general (viridans streptococci) due to 
suboptimal minimal inhibitory concentrations.  Our use of the higher dose of levofloxacin at 750 
mg daily may have mitigated these susceptibility problems.  Thus, we found no evidence in our 
study that levofloxacin prophylaxis led to adverse consequences as reflected by the emergence 
of antibiotic resistance or a change in the pattern of infections. 
 The relapse-free survival curves were indistinguishable during the period of neutropenia 
when the antibiotic activity is operative, demonstrating no evidence of superiority for one 
prophylaxis regimen over the other.  There was a trend towards better long-term relapse free 
survival in the levofloxacin group (p=0.13), but this result must be interpreted with caution 
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because the patients were treated with levofloxacin and ceftazidime in different time periods.  
Thus improvements in overall care in the later time period may account for better survival in the 
levofloxacin group.  On the other hand, an analysis of RFS by year of transplant over the study 
period showed no such trend (data not shown). 
 There were some limitations to our study.  First, this was not a randomized trial 
comparing two antibiotic prophylaxis regimens, but rather a retrospective analysis of two cohorts 
from sequential time periods.  Our goal was to assess the clinical and microbiological impact of 
adopting levofloxacin antibiotic prophylaxis for myeloablative allogeneic transplant at one HCT 
center that previously used a beta-lactam antibiotic for prophylaxis.  Definitive conclusions about 
the relative efficacy of these antibiotics would require a randomized controlled trial.  We 
adjusted our models when appropriate for observed differences in gender and cell source 
between prophylaxis groups, but there may have been other factors related to changes in 
hospital practices over time for which we could not adjust.  For example, the choice of antibiotic 
to be used for breakthrough fever on prophylaxis was left to the patient care teams, thus there 
were differences in antibiotic usage patterns within a prophylaxis group. Second, although 
levofloxacin resistance did not emerge as an important problem, ongoing use of an antibiotic in 
a community may alter the pathogens encountered on a longer time scale.  Continued vigilance 
is necessary. Third, the study reflects the experience at a single transplant center, and may not 
be applicable to patients receiving non-myeloablative or autologous transplants. Fourth, there 
were a variety of reasons that prophylactic antibiotics were stopped or changed, including 
persistent fever and drug toxicity, and this study did not focus on the reasons for antibiotic 
failure or the incidence of toxicity. Fifth, the difference in antibiotic costs was very conservative 
and based only on drug acquisition costs. Since levofloxacin is administered once daily (oral or 
intravenous), whereas ceftazidime is administered 3 times a day intravenously, the total 
administration costs of ceftazidime are likely to be substantially higher than levofloxacin. We did 
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not calculate the administration costs of these medications because different institutions charge 
very different rates making the comparison less useful.  
 In conclusion, levofloxacin is an attractive antibiotic for prophylaxis in patients 
undergoing myeloablative allogeneic HCT and compared favorably to ceftazidime.  The use of 
levofloxacin was associated with lower antibiotic acquisition costs and a reduction in significant 
bloodstream infections compared to ceftazidime. Levofloxacin resistant bacteria were detected 
in patients receiving levofloxacin prophylaxis but there was no significant increase in antibiotic 
resistant bacteria. Although patients receiving levofloxacin prophylaxis had a higher rate of 
developing fever, these patients were usually switched to ceftazidime, thereby helping to 
preserve extended spectrum antibiotics such as imipenem for those who fail empirical therapy. 
This strategy may help to further limit costs and the emergence of antibiotic resistance.  
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Table 1. Characteristics by prophylaxis regimen 
 Ceftazidime Levofloxacin 
Number of patients 216 219 
Sex (number, percent male) 107 (50) 132 (60) 
Age (median, range in years) 42 (19 – 66) 43 (19 – 67) 
Diagnosis (number, percent)   
   Aplastic anemia 6 (3) 2 (1) 
   Acute lymphoblastic leukemia 24 (11) 26 (12) 
   Acute myeloid leukemia 65 (30) 77 (35) 
   Chronic myeloid leukemia 50 (23) 46 (21) 
   Myelodysplastic syndrome 52 (24) 55 (25) 
   Non-Hodgkin’s lymphoma 12 (6) 9 (4) 
   Other 7 (4) 4 (2) 
Disease risk (number, percent)   
   Nonadvanced 152 (70) 145 (66) 
   Advanced 61 (28) 67 (31) 
   Missing 3 (1) 7 (3) 
Conditioning regimen (number, percent)   
   Bu/Cy 94 (44) 112 (51) 
   Bu/Cy/ATG 2 (1) 19 (9) 
   Bu/Flu 14 (6) 8 (4) 
   Cy/TBI 99 (46) 70 (32) 
   Other 7 (3) 10 (5) 
Donor match (number, percent)   
   Related 108 (50) 98 (45) 
   Unrelated 108 (50) 121 (55) 
Cell source (number, percent)   
   Bone marrow 61 (28) 42 (19) 
   Peripheral blood stem cell 150 (69) 177 (81) 
   BM, PBSC 3 (1) 0 
   Cord blood 2 (1) 0 
Abbreviations: Bu=Busulfan, Cy=Cytoxan, ATG= Anti-thymocyte globulin,  




Table 2. Changes in antibiotic therapy after stopping initial regimen 
 Ceftazidime Levofloxacin 
Number of patients 216 219 
% of patients with antibiotic changes 45% 63% 
Number of antibiotic changes 98 139 
New therapy (per number of changes)   
   Aztreonam 3 (3) 4 (3) 
   Ceftazidime 5 (5) 121 (87) 
   Ciprofloxacin 20 (20) 1 (1) 
   Clindamycin 1 (1) 4 (3) 
   Gentamicin 9 (9) 14 (10) 
   Imipenem 71 (72) 39 (28) 
   Levofloxacin 17 (17) 6 (4) 





Table 3. Etiology of bacteremic episodes diagnosed during first 100 days post-transplant 







Gram negative bacteremias   
     Pseudomonas 3 3 
     Acinetobacter 0 5 
     Serratia 2 5 
     Stenotrophomonas 1 1 
     Total 14* 19* 
   
Gram positive bacteremias   
     Coagulase negative staphylococci 122* 107* 
     Staphylococcus aureus 2 1 
     Viridans streptococci 10 8 
     Enterococci 23 12 
     Bacillus spp 8 2 
     Corynebacteria 16 6 
     Listeria 0 1 
     Total 179* 137* 
   
Anaerobic bacteremias 4 4 
Mycobacterial bacteremias (M. avium) 1 0 
Polymicrobial bacteremias 16 11 
Recovery of any bacterium was recorded, including single isolates of CoNS or Corynebacteria 
* Includes polymicrobial bacteremias 
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Table 4. Incidence of antibiotic resistance by prophylaxis regimen 
    Resistance 
 Patient Episode Day Ceftazidime Levofloxacin 
Pseudomonas      
   Ceftazidime cohort 1 1 39 Intermediate Resistant 
 1 2 56 Sensitive Resistant 
 2 1 93 Sensitive Sensitive 
   Levofloxacin cohort 3 1 54 Sensitive Sensitive 
 4 1 14 Sensitive Resistant 
 5 1 48 Sensitive Sensitive 
Acinetobacter      
   Levofloxacin cohort 1 1 53 Sensitive Sensitive 
 2 1 42 Resistant Resistant 
 2 2 57 Resistant Resistant 
 2 3 86 Resistant Resistant 
 3 1 65 Sensitive Sensitive 
Serratia      
   Ceftazidime cohort 1 1 29 Sensitive Sensitive 
 1 2 47 Sensitive Sensitive 
   Levofloxacin cohort 2 1 55 Sensitive Intermediate 
 3 1 31 Sensitive Sensitive 
 3 2 42 Sensitive Sensitive 
 4 1 91 Sensitive Sensitive 
 5 1 48 Sensitive Sensitive 
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Titles and legends to figures 
 
Figure 1. Time to fever by initial prophylaxis regimen. The p-value results from a proportional 
hazards regression model adjusted for cell source and donor type. 
 
Figure 2. Time to first bacteremia, excluding single-organism coagulase-negative 
Staphylococcus (CoNS) infection, by initial prophylaxis regimen. The p-value results from an 
unadjusted proportional hazards regression model. 
 
Figure 3. Time to the first of any infection in blood (excluding CoNS), urine, respiratory or wound 
culture by initial prophylaxis regimen. The p-value results from a proportional hazards 
regression model adjusted for sex. 
 
Figure 4. Relapse-free survival by initial prophylaxis regimen.  The p-value results from a 
proportional hazards regression model adjusted for cell source and TBI exposure. 
 
 
 
